91 Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin
AimsDeterioration in ventricular function is often observed in patients treated with anthracyclines for cancer. There is a paucity of evidence on interventions that might provide cardio-protection. We investigated whether carvedilol can prevent doxorubicin-induced cardiotoxicity and whether any obse...
Gespeichert in:
| Veröffentlicht in: | Heart (British Cardiac Society) 2018-06, Vol.104 (Suppl 6), p.A76-A76 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | A76 |
|---|---|
| container_issue | Suppl 6 |
| container_start_page | A76 |
| container_title | Heart (British Cardiac Society) |
| container_volume | 104 |
| creator | Kinsara, Abdulhalim abuosa, Ahmed Elsheikh, Ayman Qureshi, Kahekashan Abrar, Mohammed Kholeif, Mona Andejani, Abdulwahab Ahmed, Adel Cleland, John |
| description | AimsDeterioration in ventricular function is often observed in patients treated with anthracyclines for cancer. There is a paucity of evidence on interventions that might provide cardio-protection. We investigated whether carvedilol can prevent doxorubicin-induced cardiotoxicity and whether any observed effect is dose related.Methods and resultsA prospective, randomised, double-blind study in patients treated with doxorubicin, comparing placebo (n=38) with different doses of carvedilol [6.25 mg/day (n=41), 12.5 mg/day (n=38) or 25 mg/day (n=37)]. The primary endpoint was the measured change in left ventricular ejection fraction (LVEF) from baseline to 6 months. LVEF decreased from 62%±5% at baseline to 58%±7% at 6 months (p=0.002) in patients assigned to placebo but no statistically significant changes were observed in any of the 3 carvedilol groups. At 6 months, only one of 116 patients (1%) assigned to carvedilol had an LVEF |
| doi_str_mv | 10.1136/heartjnl-2018-BCS.90 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_bmj_p</sourceid><recordid>TN_cdi_proquest_journals_2480807864</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2480807864</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1140-b89a00b5c8dae1867c8e19dda548f394acbe4a22abf212c9ab16d3398526fc963</originalsourceid><addsrcrecordid>eNo1kM1KAzEUhYMoWKtv4CLgetpkkkmTpRb_oKCggruQv6EZppMxk2ntzo0v6pM4Q3Vz7-Xcc-6FD4BLjGYYEzZfOxVT1dRZjjDPbpYvM4GOwARTxkfp_XiYSVFkDJHFKTjrugohRAVnE7AT-Ofr-zmGdr2vlUnewL5zMJTQqLh11tehhinANrqtaxIcS_Smr1WEdt-VfTNkQgN9A1uV_LDt4M6n9RBvjIswRaeSswfNhs8Qe-2Nb87BSanqzl389Sl4u7t9XT5kq6f7x-X1KtMYU5RpLhRCujDcKoc5WxjusLBWFZSXRFBltKMqz5Uuc5wboTRmlhDBi5yVRjAyBVeHu20MH73rkqxCH5vhpcwpRxwtOKODa35w6U0l2-g3Ku4lRnKkK__pypGuHOhKgcgvh-N0DQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2480807864</pqid></control><display><type>article</type><title>91 Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin</title><source>PubMed Central</source><creator>Kinsara, Abdulhalim ; abuosa, Ahmed ; Elsheikh, Ayman ; Qureshi, Kahekashan ; Abrar, Mohammed ; Kholeif, Mona ; Andejani, Abdulwahab ; Ahmed, Adel ; Cleland, John</creator><creatorcontrib>Kinsara, Abdulhalim ; abuosa, Ahmed ; Elsheikh, Ayman ; Qureshi, Kahekashan ; Abrar, Mohammed ; Kholeif, Mona ; Andejani, Abdulwahab ; Ahmed, Adel ; Cleland, John</creatorcontrib><description>AimsDeterioration in ventricular function is often observed in patients treated with anthracyclines for cancer. There is a paucity of evidence on interventions that might provide cardio-protection. We investigated whether carvedilol can prevent doxorubicin-induced cardiotoxicity and whether any observed effect is dose related.Methods and resultsA prospective, randomised, double-blind study in patients treated with doxorubicin, comparing placebo (n=38) with different doses of carvedilol [6.25 mg/day (n=41), 12.5 mg/day (n=38) or 25 mg/day (n=37)]. The primary endpoint was the measured change in left ventricular ejection fraction (LVEF) from baseline to 6 months. LVEF decreased from 62%±5% at baseline to 58%±7% at 6 months (p=0.002) in patients assigned to placebo but no statistically significant changes were observed in any of the 3 carvedilol groups. At 6 months, only one of 116 patients (1%) assigned to carvedilol had an LVEF <50% compared to four of the 38 assigned to placebo (11%), (p=0.013). No significant differences were noted between carvedilol and placebo in terms of the development of diastolic dysfunction, clinically overt heart failure or death.ConclusionsCarvedilol might prevent deterioration in LVEF in cancer patients treated with doxorubicin. This effect may not be dose related within the studied range</description><identifier>ISSN: 1355-6037</identifier><identifier>EISSN: 1468-201X</identifier><identifier>DOI: 10.1136/heartjnl-2018-BCS.90</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Cancer</subject><ispartof>Heart (British Cardiac Society), 2018-06, Vol.104 (Suppl 6), p.A76-A76</ispartof><rights>2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2018 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Kinsara, Abdulhalim</creatorcontrib><creatorcontrib>abuosa, Ahmed</creatorcontrib><creatorcontrib>Elsheikh, Ayman</creatorcontrib><creatorcontrib>Qureshi, Kahekashan</creatorcontrib><creatorcontrib>Abrar, Mohammed</creatorcontrib><creatorcontrib>Kholeif, Mona</creatorcontrib><creatorcontrib>Andejani, Abdulwahab</creatorcontrib><creatorcontrib>Ahmed, Adel</creatorcontrib><creatorcontrib>Cleland, John</creatorcontrib><title>91 Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin</title><title>Heart (British Cardiac Society)</title><description>AimsDeterioration in ventricular function is often observed in patients treated with anthracyclines for cancer. There is a paucity of evidence on interventions that might provide cardio-protection. We investigated whether carvedilol can prevent doxorubicin-induced cardiotoxicity and whether any observed effect is dose related.Methods and resultsA prospective, randomised, double-blind study in patients treated with doxorubicin, comparing placebo (n=38) with different doses of carvedilol [6.25 mg/day (n=41), 12.5 mg/day (n=38) or 25 mg/day (n=37)]. The primary endpoint was the measured change in left ventricular ejection fraction (LVEF) from baseline to 6 months. LVEF decreased from 62%±5% at baseline to 58%±7% at 6 months (p=0.002) in patients assigned to placebo but no statistically significant changes were observed in any of the 3 carvedilol groups. At 6 months, only one of 116 patients (1%) assigned to carvedilol had an LVEF <50% compared to four of the 38 assigned to placebo (11%), (p=0.013). No significant differences were noted between carvedilol and placebo in terms of the development of diastolic dysfunction, clinically overt heart failure or death.ConclusionsCarvedilol might prevent deterioration in LVEF in cancer patients treated with doxorubicin. This effect may not be dose related within the studied range</description><subject>Cancer</subject><issn>1355-6037</issn><issn>1468-201X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNo1kM1KAzEUhYMoWKtv4CLgetpkkkmTpRb_oKCggruQv6EZppMxk2ntzo0v6pM4Q3Vz7-Xcc-6FD4BLjGYYEzZfOxVT1dRZjjDPbpYvM4GOwARTxkfp_XiYSVFkDJHFKTjrugohRAVnE7AT-Ofr-zmGdr2vlUnewL5zMJTQqLh11tehhinANrqtaxIcS_Smr1WEdt-VfTNkQgN9A1uV_LDt4M6n9RBvjIswRaeSswfNhs8Qe-2Nb87BSanqzl389Sl4u7t9XT5kq6f7x-X1KtMYU5RpLhRCujDcKoc5WxjusLBWFZSXRFBltKMqz5Uuc5wboTRmlhDBi5yVRjAyBVeHu20MH73rkqxCH5vhpcwpRxwtOKODa35w6U0l2-g3Ku4lRnKkK__pypGuHOhKgcgvh-N0DQ</recordid><startdate>201806</startdate><enddate>201806</enddate><creator>Kinsara, Abdulhalim</creator><creator>abuosa, Ahmed</creator><creator>Elsheikh, Ayman</creator><creator>Qureshi, Kahekashan</creator><creator>Abrar, Mohammed</creator><creator>Kholeif, Mona</creator><creator>Andejani, Abdulwahab</creator><creator>Ahmed, Adel</creator><creator>Cleland, John</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201806</creationdate><title>91 Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin</title><author>Kinsara, Abdulhalim ; abuosa, Ahmed ; Elsheikh, Ayman ; Qureshi, Kahekashan ; Abrar, Mohammed ; Kholeif, Mona ; Andejani, Abdulwahab ; Ahmed, Adel ; Cleland, John</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1140-b89a00b5c8dae1867c8e19dda548f394acbe4a22abf212c9ab16d3398526fc963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kinsara, Abdulhalim</creatorcontrib><creatorcontrib>abuosa, Ahmed</creatorcontrib><creatorcontrib>Elsheikh, Ayman</creatorcontrib><creatorcontrib>Qureshi, Kahekashan</creatorcontrib><creatorcontrib>Abrar, Mohammed</creatorcontrib><creatorcontrib>Kholeif, Mona</creatorcontrib><creatorcontrib>Andejani, Abdulwahab</creatorcontrib><creatorcontrib>Ahmed, Adel</creatorcontrib><creatorcontrib>Cleland, John</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Heart (British Cardiac Society)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kinsara, Abdulhalim</au><au>abuosa, Ahmed</au><au>Elsheikh, Ayman</au><au>Qureshi, Kahekashan</au><au>Abrar, Mohammed</au><au>Kholeif, Mona</au><au>Andejani, Abdulwahab</au><au>Ahmed, Adel</au><au>Cleland, John</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>91 Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin</atitle><jtitle>Heart (British Cardiac Society)</jtitle><date>2018-06</date><risdate>2018</risdate><volume>104</volume><issue>Suppl 6</issue><spage>A76</spage><epage>A76</epage><pages>A76-A76</pages><issn>1355-6037</issn><eissn>1468-201X</eissn><abstract>AimsDeterioration in ventricular function is often observed in patients treated with anthracyclines for cancer. There is a paucity of evidence on interventions that might provide cardio-protection. We investigated whether carvedilol can prevent doxorubicin-induced cardiotoxicity and whether any observed effect is dose related.Methods and resultsA prospective, randomised, double-blind study in patients treated with doxorubicin, comparing placebo (n=38) with different doses of carvedilol [6.25 mg/day (n=41), 12.5 mg/day (n=38) or 25 mg/day (n=37)]. The primary endpoint was the measured change in left ventricular ejection fraction (LVEF) from baseline to 6 months. LVEF decreased from 62%±5% at baseline to 58%±7% at 6 months (p=0.002) in patients assigned to placebo but no statistically significant changes were observed in any of the 3 carvedilol groups. At 6 months, only one of 116 patients (1%) assigned to carvedilol had an LVEF <50% compared to four of the 38 assigned to placebo (11%), (p=0.013). No significant differences were noted between carvedilol and placebo in terms of the development of diastolic dysfunction, clinically overt heart failure or death.ConclusionsCarvedilol might prevent deterioration in LVEF in cancer patients treated with doxorubicin. This effect may not be dose related within the studied range</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/heartjnl-2018-BCS.90</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1355-6037 |
| ispartof | Heart (British Cardiac Society), 2018-06, Vol.104 (Suppl 6), p.A76-A76 |
| issn | 1355-6037 1468-201X |
| language | eng |
| recordid | cdi_proquest_journals_2480807864 |
| source | PubMed Central |
| subjects | Cancer |
| title | 91 Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T04%3A18%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=91%E2%80%85Prophylactic%20use%20of%20carvedilol%20to%20prevent%20ventricular%20dysfunction%20in%20patients%20with%20cancer%20treated%20with%20doxorubicin&rft.jtitle=Heart%20(British%20Cardiac%20Society)&rft.au=Kinsara,%20Abdulhalim&rft.date=2018-06&rft.volume=104&rft.issue=Suppl%206&rft.spage=A76&rft.epage=A76&rft.pages=A76-A76&rft.issn=1355-6037&rft.eissn=1468-201X&rft_id=info:doi/10.1136/heartjnl-2018-BCS.90&rft_dat=%3Cproquest_bmj_p%3E2480807864%3C/proquest_bmj_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2480807864&rft_id=info:pmid/&rfr_iscdi=true |